https://tie2-signaling.com/ind....ex.php/beginning-and
Eventually, clinical experiments indicated that aptamer MF3Ec could distinguish Luminal A breast cancer tumors subtype from Luminal B (HER2+), HER2-enriched, and triple-negative breast cancer subtypes, para-carcinoma tissues and typical breast areas. Collectively, every one of these results claim that aptamer MF3Ec is a promising probe for exact discrimination and specific therapy of Luminal A breast cancer molecular subtype.In this review, recent development into the application of CO
Like
Comment
Share
